BioSpace News Archive

Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that management will present at the 2021 Wedbush PacGrow Virtual Healthcare Conference on Wednesday, August 11, 2021 at 1:45 p.m. Eastern Time.

INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today reported its financial results for the second quarter ended June 30, 2021 and provided a business update.

MAIA Biotechnology, Inc., a targeted therapy, immuno-oncology company focused on developing first-in-class oncology drugs, today announced that it has appointed Mihail Obrocea, M.D., as Chief Medical Officer and Head of Development, and Charlotte Tsou as an independent member of its board of directors.

Alphatec Holdings, Inc. announced its intention to offer, subject to market and other conditions, $250,000,000 aggregate principal amount of convertible senior notes due 2026 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), today announced that the Company’s novel, once-daily oral and intravenous antibiotic NUZYRA®(omadacycline) has recently been added to the Center for Disease Control and Prevention’s (CDC) updated report, “Antimicrobial Treatment and Prophylaxis of Plague: Recommendations for Naturally Acquired Infections and Bioterrorism Response”.

Rapid Micro Biosystems, Inc. announced that the underwriters of its previously announced initial public offering of Class A common stock have exercised their option to purchase additional shares in part for 1,086,604 shares at the public offering price of $20.00 per share less underwriting discounts and commissions, for additional gross proceeds to Rapid Micro of $21.7 million.

vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the second quarter ended June 30, 2021, and provided an update on the progress of its clinical programs.

SQZ Biotechnologies, focused on unlocking the full potential of cell therapies for multiple therapeutic areas, reported second quarter 2021 financial results and recent portfolio updates.

The controlled use of pesticides is an important tool for the agricultural sector.

Tarsus Pharmaceuticals, Inc., a late clinical-stage biopharmaceutical company whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, announced financial results and provided business and clinical updates for the quarter ended June 30, 2021.